The Quest to Cure HIV
HIV (human immunodeficiency virus) remains one of the world's most serious public health challenges. Since first being identified in the early 1980s, around 80 million people have been infected with HIV and almost 40 million people have died from AIDS-related illnesses. While great strides have been made in treatment, allowing many of those living with HIV to manage it as a chronic condition rather than a death sentence, there is still no cure.
The standard HIV treatment involves lifelong antiretroviral therapy (ART) medications to suppress viral replication and support the immune system. However, ART does not fully restore health nor eliminate HIV from the body. This means if ART is stopped, the virus generally comes back to high levels within weeks.
But now, after decades of stalemate, progress towards an HIV cure is accelerating as researchers uncover insights that may allow HIV reservoirs in the body to be targeted and purged. While developing a safe, scalable, and effective cure is still a monumental challenge, ongoing clinical trials and cutting-edge discoveries are bringing renewed hope that eliminating HIV from the human body might just be possible.
The Complex Challenge of Curing HIV
HIV cure research aims for one of two goals: a sterilizing cure that fully eradicates all traces of replication-competent HIV from the body, or a functional cure where HIV remains in the body but is controlled naturally without ART.
However, achieving either is exceptionally difficult due to HIV's ability to integrate itself into human DNA and lie dormant as a reservoir that evades the immune system. When ART is stopped, the virus can reactivate and replicate rapidly. HIV reservoirs include latent viral populations found in several immune cell types and anatomical sites, with research indicating they can persist indefinitely.
With current technology, completely eliminating or permanently silencing these HIV reservoirs with treatments appears unfeasible. But some pioneering research directions offer hope that a functional cure may be within reach.
Encouraging Cases of HIV Remission and Cure
While still extremely rare, there are a few remarkable cases that prove HIV remissiona long-term control of the virus without ARTis possible.
The most well-known is the Berlin patient Timothy Brown who has remained free of replicating HIV since 2008, representing the one sterilizing cure case so far. He underwent a complex and risky procedure of stem cell transplants from a donor with an uncommon genetic mutation conferring HIV resistance. Attempts to replicate this outcome in other HIV patients have not been successful so far.
More recently came news of a woman referred to as the New York patient who achieved an extended period of HIV remission for the first time without undergoing a risky bone marrow transplant. After receiving an experimental mix of ART medications for several months tailored to her unique viral genotype, signs of replicating HIV became undetectable, including in hidden viral reservoirs. While technically still infected with HIV, she has exhibited no signs of viral activity after discontinuing treatment since 2017.
In early 2022, researchers also reported that a group of 14 people with HIV who began ART very shortly after becoming infected had no detectable virus in blood samples after stopping treatment. While viral reservoirs likely still existed in tissues, it demonstrated that early treatment may limit reservoir seeding and make future remission more achievable for some.
Cutting-Edge Research Pathways for an HIV Cure
The knowledge gained from exceptional patient cases is now being translated into several pioneering clinical trials and scientific initiatives to move towards scalable curative therapies.
One major research avenue focuses on adjuvant immunotherapies to make latent HIV reservoirs visible again to the immune system, enabling their clearance from the body. Strategies in testing involve vaccines designed to induce new HIV-specific immune responses and monoclonal antibodies engineered to grab onto viral proteins.
Gene therapies utilizing tools like CRISPR to delete, alter or silence HIV DNA sequences are also undergoing investigation. Other radical approaches attempt to supercharge killer immune cells to actively hunt reservoirs or engineer stem cells to resist infection.
While years or decades more research is likely needed, scientists are increasingly optimistic that combining ART treatment with these emerging curative approaches can enable long-term HIV remission and restricted viral activity for broad patient groups.
Treatment Leading to HIV Cure in Diverse Patients
One remarkable recent case provided compelling evidence that HIV cures may be possible for demographically diverse groups by coupling standard ART treatment with experimental reservoir-targeting compounds.
In early 2022, researchers reported that a middle-aged woman of mixed-race ancestry living with HIV attained undetectable levels of the virus after receiving an experimental kick and kill therapy regimen in addition to her regular ART treatment. She would be the third person and first woman to ever be potentially cured of HIV.
The Case of the New York Patient
The woman was originally diagnosed with HIV in 2013 and began standard ART treatment, reaching undetectable viral levels in the blood within 9 months. However, traces of HIV genetic material could still be detected, indicating the virus was hiding dormant inside viral reservoirs established early in the infection.
In 2017, she enrolled in the clinical trial named IMPAACT P1107 at Weill Cornell Medicine and University of California hospitals. The trials strategy was to intensify ART therapy for 6 months with medications selected to match the patients unique viral genotype, aiming to maximally suppress HIV activity in all reservoirs.
This intensive ART phase was also paired with two monoclonal antibody drugs designed to kick latent virus out of hiding. After 45 weeks, all ART and antibodies would be stopped while closely monitoring for viral rebounds.
Amazingly, 14 months after halting all treatments testing has uncovered zero traces of replicating HIV in her blood or extensively sampled tissues, positioning her as potentially the third person cured of HIV and the first woman.
Significance for Diverse and Minority Communities
While longer monitoring is still required, researchers expressed excitement at the wider implications of this case for translating curative therapies to groups that are disproportionally impacted by HIV but historically overlooked for clinical resources.
Most notably, the patient was of mixed-race heritage, whereas the two prior cases of HIV remission occurred in white men. Her cure suggests that immunological distinctions among races may not pose barriers to certain curative approaches as once feared.
Additionally, minority groups like Black and Latino communities account for high proportions of new HIV casesover 40% in recent years. Her cure is the first indication that similar reservoir-targeting treatment regimens could be effective despite genetic variability across races.
Researchers concluded that genetic ancestry should not determine access to HIV cure initiatives going forward. With further research, curative clinical trials could be opened to minorities who currently lack adequate HIV treatment resources to meaningfully evaluate and advance therapies towards a widely accessible cure.
Looking Ahead in the Search for an HIV Cure
While not quite yet a confirmed sterilizing cure, the remarkable results from this woman and a small but growing number of analogous cases provide genuine motivation that a scalable HIV cure strategy may be close at hand.
Much work remains both scientifically and economically to translate these cutting-edge but highly resource-intensive approaches into accessible therapies. But there exists great confidence from leading HIV experts that combined ART treatment and immunotherapy will one day allow long-term suppression of viral activity and harmful effects of the virus - bringing hope and health to the millions worldwide living with HIV.
FAQs
What is the difference between an HIV sterilizing cure versus a functional cure?
A sterilizing cure would fully eliminate all replication-competent HIV from someone's body, while a functional cure would not eliminate HIV but would enable long-term viral control without the need for lifelong antiretroviral therapy (ART).
What are some of the main strategies being researched for an HIV cure?
Major research avenues focus on using immunotherapy approaches like vaccines, monoclonal antibodies, or engineered immune cells to target and clear HIV reservoirs. Gene therapies using CRISPR to edit HIV DNA sequences are also being explored. These strategies aim to be used alongside standard ART treatment.
Who are some notable HIV cure or remission cases?
The Berlin patient, Timothy Brown, remains the only person to have been sterilizingly cured of HIV. More recent cases like the New York patient and a group known as the IMPAACT P1107 have achieved long periods of HIV remission for years after stopping ART treatment.
How achievable is an HIV cure that works for diverse racial groups?
One remarkable recent case who may represent the first woman cured of HIV has provided promising indications that immunotherapy-based curative approaches could be effective across racial groups. This has increased optimism around developing broadly accessible HIV cures.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.
Add Comment